Literature DB >> 17507354

Prevalence and prognostic impact of comorbidities in heart failure patients with implantable cardioverter defibrillator.

Christian Bruch1, Chahrebanu Bruch, Jürgen Sindermann, Günter Breithardt, Rainer Gradaus.   

Abstract

AIMS: This study assessed the prevalence and the prognostic impact of comorbidities in heart failure patients with implantatable cardioverter-defibrillator (ICD). METHODS AND
RESULTS: We prospectively enrolled 146 patients with chronic heart failure, an ICD, and systolic dysfunction (mean ejection fraction 29 +/- 10%). Cardiac death was chosen as the primary endpoint. Death or appropriate ICD therapy, i.e. antitachycardia pacing/shock due to sustained ventricular tachycardia or ventricular fibrillation, was chosen as the secondary endpoint. Seventy-five patients (52%) had chronic kidney disease (defined as an estimated glomerular filtration rate <60 mL/min/1.73 m(2)), 39 patients (27%) were anaemic, and 34 patients (23%) had diabetes mellitus. During a follow-up of 663 +/- 400 days, 22 patients (15%) died, and 41 patients (28%) received an appropriate ICD therapy. By multivariate Cox analysis, independent predictors of cardiac death were chronic kidney disease, age, and NYHA functional class. Death/appropriate ICD therapy were independently predicted by chronic kidney disease and QRS duration. In the presence of chronic kidney disease, outcome was significantly worse when compared with the absence (event-free survival rate 51 vs. 76%, P < 0.001).
CONCLUSION: In heart failure patients with an ICD, comorbidities are frequent but only the presence of chronic kidney disease is independently associated with increased morbidity and mortality.

Entities:  

Mesh:

Year:  2007        PMID: 17507354     DOI: 10.1093/europace/eum097

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  5 in total

1.  Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter-Defibrillator Therapies.

Authors:  Alexandra M Hajduk; Jerry H Gurwitz; Grace Tabada; Frederick A Masoudi; David J Magid; Robert T Greenlee; Sue Hee Sung; Andrea E Cassidy-Bushrow; Taylor I Liu; Kristi Reynolds; David H Smith; Frances Fiocchi; Robert Goldberg; Thomas M Gill; Nigel Gupta; Pamela N Peterson; Claudio Schuger; Humberto Vidaillet; Stephen C Hammill; Heather Allore; Alan S Go
Journal:  J Am Geriatr Soc       Date:  2019-03-20       Impact factor: 5.562

2.  EuroSCORE overestimates the risk of cardiac surgery: results from the national registry of the German Society of Thoracic and Cardiovascular Surgery.

Authors:  J F Gummert; A Funkat; B Osswald; A Beckmann; W Schiller; A Krian; F Beyersdorf; A Haverich; J Cremer
Journal:  Clin Res Cardiol       Date:  2009-03-05       Impact factor: 5.460

3.  The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality.

Authors:  Dominic A M J Theuns; Beat A Schaer; Osama I I Soliman; David Altmann; Christian Sticherling; Marcel L Geleijnse; Stefan Osswald; Luc Jordaens
Journal:  Europace       Date:  2010-09-10       Impact factor: 5.214

4.  Potential value of automated daily screening of cardiac resynchronization therapy defibrillator diagnostics for prediction of major cardiovascular events: results from Home-CARE (Home Monitoring in Cardiac Resynchronization Therapy) study.

Authors:  Stefan Sack; Christian Michael Wende; Herbert Nägele; Amos Katz; Wolfgang Rudolf Bauer; Craig Scott Barr; Klaus Malinowski; Harald Schwacke; Francisco Leyva; Jochen Proff; Sergey Berdyshev; Vincent Paul
Journal:  Eur J Heart Fail       Date:  2011-09       Impact factor: 15.534

5.  Predictors of mortality amongst recipients of implantable cardioverter defibrillators for secondary prevention of cardiac arrest.

Authors:  Sunil K Agarwal; Ish Singla; Haitham Hreybe; Samir Saba
Journal:  Indian Pacing Electrophysiol J       Date:  2007-10-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.